Sun Pharma Q2 net profit falls 36% on one-time charges, revenue rises 12%
Exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs, weighed on profit, while India formulation sales grew 17.3 per cent
)
Sun Pharma reported a 36% decline in Q2 net profit to ₹1,988.5 crore, weighed down by exceptional charges. | Image: Bloomberg
Listen to This Article
Sun Pharmaceutical Industries, India’s largest drugmaker, on Friday reported a 36 per cent year-on-year decline in consolidated net profit to ₹1,988.5 crore for the second quarter of 2026-27 (FY27), weighed down by exceptional charges.
Revenues from operations rose 11.9 per cent to ₹16,198.7 crore.
The company reported exceptional charges of ₹1,268.8 crore, comprising ₹922.7 crore on settling a piece of antitrust litigation in the United States (US) and ₹346.2 crore on expenses related to its proposed acquisition of Organon.
Excluding exceptional items, adjusted net profit stood at ₹3,162 crore, up 1.4 per cent year-on-year.
The company said the margin was lower than a year earlier because the quarter a year ago had benefited from sales of generic lenalidomide, a product now facing erosion in the US. The gross margin improved to 80.8 per cent. The effective tax rate rose to 28.3 per cent from 24.7 per cent.
Also Read
The results were announced during market hours. Sun Pharma shares rose 0.8 per cent to close at ₹1,778.25 on the BSE.
“Our performance during the quarter was driven by strong momentum in India, emerging markets and the rest of the world,” said Kirti Ganorkar, managing director.
He highlighted US approval for Ilumya in treating adults with active psoriatic arthritis and the preferred recommendation from the National Comprehensive Cancer Network (NCCN) for Unloxcyt in advanced cutaneous squamous cell carcinoma.
India leads growth
Formulation sales in India rose 17.3 per cent to ₹5,552.3 crore, accounting for 34.5 per cent of consolidated sales. Sun Pharma’s market share increased to 8.6 per cent from 8.3 per cent, according to Pharmarack’s moving annual total (MAT) data for September, retaining its position as the country’s largest pharmaceutical company.
The company launched 14 products during the quarter and 19 in the first half of FY27.
US sales decline
US formulation sales fell 8.2 per cent to $455 million, accounting for about 27 per cent of the total, hurt by erosion in generic lenalidomide sales. However, sales grew 6.5 per cent sequentially, supported by five generic launches.
On the earnings call, management also acknowledged a slowdown in Ilumya sales in the US.
Richard Ashcroft, chief executive officer of North America, said the causes were mixed.
“I think there’s a bit of market, but frankly, part of it is execution as well, and that’s the intervention we’ve put in place,” he said.
The global innovative-medicine business grew 6.9 per cent to $356 million. Emerging-market formulation sales rose 7.6 per cent to $350 million, while rest-of-the-world formulation sales increased 3.1 per cent to $241 million. Sales of external active pharmaceutical ingredients (APIs) grew 13.7 per cent to ₹488.9 crore.
Organon acquisition on track
On the proposed Organon acquisition, Sun Pharma said integration planning was progressing as scheduled, with regulatory approvals secured in most regions. The transaction remains on track for closure in the fourth quarter of FY27.
The company indicated that acquisition-related expenses would continue to be recognised as it moves towards closing the transaction.
R&D spending and guidance
Expenditure on research & development (R&D) for the quarter stood at ₹778.4 crore, or 4.8 per cent of sales, with innovative R&D accounting for 32.4 per cent of the total.
“These numbers are tracking lower than our intended R&D spend, but we expect the second half of the year to catch up with some of this R&D spend,” said Dilip Shanghvi, chairman.
Asked whether double-digit revenue growth in the first half would prompt an upgrade to its full-year guidance, management held firm.
“We’ll stick to what guidance we have given at the beginning of the year,” the company said, referring to its high single-digit revenue growth forecast.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Oct 30 2026 | 8:31 PM IST
